secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtaiBeckley Inc. (ATAI)
CIK:        0002081043
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001140361-26-006118
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtaiBeckley appoints Michael Faerm CFO effective March 9, 2026; Johnson becomes CAO
--------------------------------------------------------------------------------

- Michael Faerm appointed CFO of AtaiBeckley, effective March 9, 2026; Anne Johnson becomes Chief Accounting Officer.
- Faerm receives $525k base salary, 40% target bonus, option for 1.275M shares, 285k RSUs (4-yr vest), and $85k sign-on bonus.
- Severance: 0.75x salary for 9 months; change-in-control: lump sum salary+target bonus plus accelerated equity vesting.
- Faerm previously CFO at Viracta Therapeutics, interim CFO at Harpoon Therapeutics, and CFO at Artiva Biotherapeutics.
- CEO cites Faerm's experience as BPL-003 nears Phase 3 and other clinical-stage programs advance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2081043/000114036126006118/0001140361-26-006118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2081043/000114036126006118/ef20066047_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-006118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer